Gene signatures of m5C regulators may predict prognosis and immunity status of patients with Ewing's sarcoma
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.114849 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Yongqin Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China. Electronic address: cyq1767698369@163.com. Hauptthemen laut MEDLINE: Sarcoma, Ewing, 5-Methylcytosine, Biomarkers, Tumor, Bone Neoplasms. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Recent studies have showed that 5-methylcytosine (m5C) can be utilized to assess the prognosis of tumors. However, the role of clinical implications of m5C modification remains unclear. The mRNA expression profiles and clinical features were downed from GEO and ICGC databases.In order to screen out m5C regulators,Univariate and multivariate Cox regression were performed. The survival rate was determined using K-M survival analysis. Then the risk model was validated in ICGC and GSE63156 two external datasets. A nomogram was created using risk level and clinical features, well validated by calibration curve. ESTIMATE, MCP-counter and GSVA algorithms were applied to assess tumor microenvironment, immune cell, and immune function. Several drugs exhibited sensitivity for potential therapy of ES. Five m5C regulators (YBX1, TET2, NOP2, DNMT3A, DNMT1) were screened out as risk signatures. The Kaplan-Meier survival analysis demonstrated that the high-risk group had a lower survival rate compared to the low-risk group(p = 0.0026). The AUC of ROC curves in 1, 3, 5 years ranged from 0.752 to 0.829. Based on the amount of risk and clinical characteristics, a nomogram was created and well validated by calibration curve.ESTIMATE, MCP-counter and GSVA algorithms were applied to assess tumor mircoenvironment, immune cell, and immune function. Several drugs exhibited sensitivity for potential therapy of ES. The present research indicated that m5C regulators (YBX1, TET2, NOP2, DNMT3A, DNMT1) play critical roles in ES progression, and provide new insight in ES prognosis prediction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China. Electronic address: cyq1767698369@163.com.
- Department of Orthopaedics, The Second Hospital of Shandong University, Jinan, Shandong, 250012,China; People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, 830001, China. Electronic address: jiaoxiej…
- Department of Orthopaedics, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.
- Sterile Supply Department, The First People Hospital of Jinan, Jinan, Shandong,250012, China.
- Department of Orthopaedics, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China. Electronic address: qilei@sdu.edu.cn.
Förderung
- Natural Science Foundation of Shandong Province
Zitieren
APA
Chen, Y., Jiao, X., Xu, B., Yang, Y., Xu, X., Yu, H., Li, K., Wang, W., & Qi, L. (2025). Gene signatures of m5C regulators may predict prognosis and immunity status of patients with Ewing's sarcoma. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.114849
Vancouver
Chen Y, Jiao X, Xu B, Yang Y, Xu X, Yu H, et al. Gene signatures of m5C regulators may predict prognosis and immunity status of patients with Ewing's sarcoma. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.114849
BibTeX
@article{Chen2025,
author = {Chen, Yongqin and Jiao, Xiejia and Xu, Biteng and Yang, Yuxuan and Xu, Xiao and Yu, Haozhi and Li, Ke and Wang, Wenhao and Qi, Lei},
title = {Gene signatures of m5C regulators may predict prognosis and immunity status of patients with Ewing's sarcoma},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.114849}
}
EUVIMED